270,000 Shares in Indivior PLC (NASDAQ:INDV) Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC bought a new position in Indivior PLC (NASDAQ:INDV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 270,000 shares of the company’s stock, valued at approximately $2,632,000. Indivior comprises 1.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INDV. Millennium Management LLC grew its position in shares of Indivior by 48.1% during the 2nd quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after acquiring an additional 160,282 shares during the period. Janus Henderson Group PLC raised its position in shares of Indivior by 14.2% during the 1st quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock valued at $9,424,000 after buying an additional 54,750 shares during the period. Clark Estates Inc. NY purchased a new stake in shares of Indivior during the 3rd quarter valued at approximately $2,477,000. AlphaCentric Advisors LLC purchased a new stake in shares of Indivior during the 3rd quarter valued at approximately $2,364,000. Finally, Susquehanna International Group Ltd. purchased a new stake in shares of Indivior during the 2nd quarter valued at approximately $3,224,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Stock Down 1.3 %

NASDAQ:INDV traded down $0.15 during trading hours on Wednesday, hitting $11.03. The company’s stock had a trading volume of 131,108 shares, compared to its average volume of 525,204. The stock has a market capitalization of $1.52 billion, a P/E ratio of -279.43 and a beta of 0.70. The stock has a fifty day moving average of $9.53 and a 200-day moving average of $12.42. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. Indivior PLC has a 52-week low of $7.33 and a 52-week high of $23.22.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The company had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. On average, equities analysts forecast that Indivior PLC will post 1.66 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on INDV. Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum dropped their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday, October 11th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.